Importation of Cancer Drugs, Respite for Mental Health, and Xylazine Tests

To combat the ongoing drug shortages in the United States, the FDA has devised a plan to import cancer drugs from China, as reported by Hill. The agency has recently confirmed its decision to allow the distribution of an additional 10 quantities of the cancer drug cisplatin, manufactured by Chinese pharmaceutical company Qilu Pharmaceutical. While cisplatin is widely used in chemotherapy treatments in the US, the imported product from China has not received official FDA approval.

Rural Retreats Offer Support during National Mental Health Crisis

Amid a nationwide mental health crisis, rural peer retreats have emerged as a valuable source of support, according to Kaiser Health News. These retreats provide a warm and temporary environment for individuals facing mental health crises that do not require immediate medical intervention. Prompted by the COVID-19 pandemic, such facilities have sprouted across numerous states in the US. Public health officials view these retreats as promising in terms of enhancing mental health care and mitigating the risks of suicide.

Intensified Testing Aims to Combat Xylazine in Illicit Drug Supply

White House officials have announced their intent to ramp up testing, treatment, and strategies to combat the presence of xylazine, colloquially known as tranq, in illegal opioid substances, as reported by the Associated Press. In April, the combination of xylazine and fentanyl raised significant concerns due to its potential to dangerously reduce heart and breathing rates when consumed by humans. Various bills in Congress aim to restrict the use of xylazine in non-veterinary, non-agricultural contexts while preserving its legitimate applications for tranquilizing horses, sheep, and other animals.

Next Article